Pfizer Moves CNS And Cardio-Metabolic Research To Cambridge, Mass., Promotes Cross-Talk With Local Scientists
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer has relocated its neuroscience and cardiovascular medicine research groups from Groton, Conn., to Cambridge, Mass. Currently in temporary labs, the research will move into permanent space in 2013. The goal is to foster cross-talk and collaboration with local scientists and with Pfizer’s CTI program in nearby Boston.
You may also be interested in...
Pfizer Revamps Neuroscience R&D – New Site, New Mandate, New Leadership
Pfizer has thoroughly revamped its approach to neuroscience R&D, emphasizing disease biology and neural circuitry, moving its research team from Groton, Conn. to Cambridge, Mass., and hiring an eminent neuroscientist to lead the group.
Pfizer Teams With Eight Boston-Area Research Institutions In $100MM Tie-Up
The collaboration is the third in its localized Centers for Therapeutic Innovation project, intended to nudge academics toward commercial projects.
Mesoblast’s Late-Stage Pipeline Could Be Game Changing: Are Investors Paying Attention?
Mesenchymal cell specialist Mesoblast came back from a near-death experience in 2016 when Teva returned a key asset. But recent success in a Phase III trial in acute GVHD has brought it some attention. Now it needs to repeat the achievement in advanced heart failure and find a partner for its burgeoning pipeline.